Aachen, Germany

Gero Gaube

This inventor holds 1 USPTO granted patent. Top assignee: Gruenenthal Gmbh. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gero Gaube. Retrieved from https://idiyas.com/inventor/gero-gaube

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gero Gaube: Innovator in Thioamino Acids

Introduction

Gero Gaube is a notable inventor based in Aachen, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of thioamino acids.

Latest Patents

Gero Gaube holds a patent for thio-alpha-amino acids of general formula (I). This invention includes methods for producing these compounds and medicaments that contain them. The patent also outlines methods for treating pain and other diseases using pharmaceutical compositions comprising the thioamino acids.

Career Highlights

Gero Gaube is associated with Gruenenthal GmbH, a company known for its focus on innovative pain management solutions. His work has contributed to advancements in the pharmaceutical industry, particularly in the development of new therapeutic agents.

Collaborations

Gero has collaborated with notable colleagues such as Boris Chizh and Matthias Gerlach. Their combined expertise has furthered research and development in their field.

Conclusion

Gero Gaube's innovative work in thioamino acids showcases his commitment to advancing medical science and improving treatment options for patients. His contributions are a testament to the importance of research and collaboration in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…